[stock_market_widget type=”card” template=”basic2″ assets=”CNTB” realtime=”true” api=”yahoo-finance”]
A clinical-stage biopharmaceutical company, Connect Biopharma Holdings Limited (NASDAQ: CNTB), shared early results from a mid-size trial testing an add-on treatment for people having severe asthma attacks. The study focused on adults and adolescents whose asthma is driven by type 2 inflammation, a common immune pathway that can swell airways and make breathing difficult. Patients received standard emergency care plus either a single under-the-skin dose of the experimental antibody rademikibart or a placebo, then were followed for about a month to see who needed more medical help.
The most talked-about number was a 66% lower rate of treatment failure over 28 days for patients who received rademikibart compared with those who received placebo. Treatment failure in this trial meant events such as death, being readmitted to hospital, returning to the emergency department, making an unscheduled clinic visit for worsening asthma, or needing stronger medications. That 66% figure did not reach the usual threshold for statistical significance, in part because fewer patients overall had these events than the study designers had expected. Still, the direction of the result points toward a meaningful clinical effect, especially when viewed alongside other measures from the same trial.
A clearer statistical signal appeared in lung function measured one week after dosing. The key metric here is FEV1, or forced expiratory volume in one second, which captures how much air a person can forcefully exhale in the first second of a big breath. Higher FEV1 generally means airways are more open. On day 7, patients given rademikibart improved by 250 milliliters from their baseline, while the placebo group improved by 120 milliliters, a difference of 130 milliliters that was statistically significant. Think of this as an early, objective sign that the drug helped lungs work better within a week, a window that matters for hospital discharge planning and recovery at home.
There were also hints of reduced health system use. The company reported about a 50% drop in emergency department visits or unscheduled medical visits for worsening asthma symptoms among patients who received rademikibart versus placebo. Fewer return visits could translate into lower costs for hospitals and insurers, and less disruption for patients and families. Safety findings were reassuring in this small study. Adverse events were infrequent and similar between groups, no one stopped the study drug because of side effects, and serious adverse events were rare, with one in the rademikibart arm and three in the placebo arm.
Why does this matter beyond one trial readout. Asthma exacerbations often cluster, meaning a person who has one attack is at higher risk of another soon after, even when using current standard therapies. An add-on treatment that can quickly improve lung function and reduce the chance of needing more care could change how hospitals manage these episodes. The company’s leadership has pointed to recent market research estimating roughly 1.6 million emergency department visits in the U.S. in 2025 for acute asthma exacerbations among patients with high type 2 inflammation, a population that could be candidates for this approach if later trials confirm benefit.
The path forward hinges on study design and regulator feedback. Connect Biopharma plans to report topline data later this month from a similar Phase 2 trial in chronic obstructive pulmonary disease, or COPD, another lung disease where type 2 inflammation can play a role. After that readout, the company intends to meet with the U.S. Food and Drug Administration to align on a Phase 3 program. Notably, the one-week FEV1 change, which was statistically significant in this asthma study, is being proposed as the primary endpoint for Phase 3, rather than the 28-day treatment failure measure that missed significance here. That choice reflects a practical lesson from the mid-stage data and could shape the size, cost, and timeline of the next trial.
This is a familiar pattern. Mid-stage trials often produce mixed signals, with some endpoints strong and others inconclusive. The art lies in using those signals to design a larger, more definitive study that answers the right question with enough patients and the right measures. In this case, the question is whether adding a single dose of an IL-4Rα blocking antibody to standard care can reliably speed recovery and prevent setbacks after a severe asthma attack. The next few months, including the COPD data and early regulator discussions, will indicate how confidently the company can pursue that question at scale.
